Literature DB >> 31207347

Mebendazole induces apoptosis via C-MYC inactivation in malignant ascites cell line (AGP01).

Laine Celestino Pinto1, Felipe Pantoja Mesquita2, Bruno Moreira Soares3, Emerson Lucena da Silva2, Bruna Puty4, Edivaldo Herculano Corrêa de Oliveira5, Rommel Rodriguez Burbano3, Raquel Carvalho Montenegro6.   

Abstract

The objective of study was to examine the role of MBZ on malignant ascites cells and the involvement of C-MYC. Comet assay was used to assess the genotoxic effects of MBZ in AGP01 cells and human lymphocytes; differential staining by ethidium bromide and acridine orange, caspase 3/7 and flow cytometry assay was done to access the mechanisms of apoptosis and cell cycle analysis of MBZ in AGP01 cells. C-MYC amplification, C-MYC mRNA and C-MYC protein expression were evaluated by FISH, RT-qPCR and Western blotting, respectively. In addition, cytotoxicity of MBZ was evaluated in AGP01 and AGP01 shRNA MYC by MTT. MBZ significantly increased the damage index and no produced in human lymphocytes. MBZ caused remarkable cell cycle arrest in G0/G1 and G2/M phases at 0.5μM and 1.0 μM, respectively and induced significantly apoptosis in higher concentrations. Additionally, MBZ (0.5 μM and 1.0 μM) increased caspase 3 and 7 activities. MBZ decreased signals, C-MYC mRNA and C-MYC protein expression in AGP01 cells. MBZ induced lower cell viability in AGP01 cells compared AGP01 shRNA MYC in the same concentration. Therefore, our results show the evidence of C-MYC gene as one of the pathways by which MBZ induces cell death in gastric cancer cells.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; C-MYC; Damage; Drug target; Gastric cancer; Mebendazole

Year:  2019        PMID: 31207347     DOI: 10.1016/j.tiv.2019.06.010

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  5 in total

Review 1.  Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature.

Authors:  Andrea Emanuele Guerini; Luca Triggiani; Marta Maddalo; Marco Lorenzo Bonù; Francesco Frassine; Anna Baiguini; Alessandro Alghisi; Davide Tomasini; Paolo Borghetti; Nadia Pasinetti; Roberto Bresciani; Stefano Maria Magrini; Michela Buglione
Journal:  Cancers (Basel)       Date:  2019-08-31       Impact factor: 6.639

2.  G2/M arrest and mitotic slippage induced by fenbendazole in canine melanoma cells.

Authors:  Sehoon Kim; Shashini Kanchanamala Perera; Seo-In Choi; Robert B Rebhun; Kyoung-Won Seo
Journal:  Vet Med Sci       Date:  2022-01-12

3.  Anticancer potential of mebendazole against chronic myeloid leukemia: in silico and in vitro studies revealed new insights about the mechanism of action.

Authors:  Julio Paulino Daniel; Felipe Pantoja Mesquita; Emerson Lucena Da Silva; Pedro Filho Noronha de Souza; Luina Benevides Lima; Lais Lacerda Brasil de Oliveira; Maria Elisabete Amaral de Moraes; Caroline de Fátima Aquino Moreira-Nunes; Rommel Mario Rodríguez Burbano; Geancarlo Zanatta; Raquel Carvalho Montenegro
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

Review 4.  Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics.

Authors:  Bomi Song; Eun Young Park; Kwang Joon Kim; Sung Hwan Ki
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575

Review 5.  The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs.

Authors:  Deok-Soo Son; Eun-Sook Lee; Samuel E Adunyah
Journal:  Immune Netw       Date:  2020-08-04       Impact factor: 6.303

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.